 |
|
 |
 |
|
THURSDAY,
AUGUST 9, 2007
Advances
in Immunotherapy
for Malignant
Melanoma
A
complimentary
dinner meeting
New York, New
York
Chair:
F. Stephen Hodi
Jr., MD
Dana Farber Cancer
Institute
Boston, Massachusetts
*FULL* |
 |
|
F A C
U L T
Y |
 |
|
|
F. Stephen Hodi Jr., MD
Dana
Farber Cancer Institute
Boston,
Massachusetts |
Vernon K. Sondak, MD
H.
Lee Moffitt Cancer Center
Tampa,
Florida |
Jedd D. Wolchok, MD, PhD
Memorial
Sloan-Kettering Cancer Center
New
York, New York |
|
|
|
S C I
E N T
I F I
C
A G E
N D A
|
|
|
6:30 pm
Registration
and reception
7:00 pm
Introduction
to the
biology
of melanoma
F.
Stephen Hodi Jr., MD
7:15
pm
Immunotherapy:
Harnessing
the immune
response
to cancer
Jedd
D. Wolchok, MD, PhD
7:45 pm
Overcoming immunologic tolerance
to
melanoma:
Targeting
CTLA-4
F.
Stephen Hodi Jr., MD
8:15
pm
Enhancing
the immune
response to melanoma: Vaccines and other novel biologics
to stimulate and target the immune response
Vernon
K. Sondak, MD
8:45 pm
Question
and answer
session
9:00 pm
Adjourn |
|
|
|
C O N
T I N
U I N
G M
E D I
C A L
E D U
C A T
I O N |
|
|
|
Imedex
Accreditation
Services,
LLC
is
accredited
by
the
Accreditation
Council
for
Continuing
Medical
Education
to
provide
continuing
medical
education
for
physicians.
Imedex
Accreditation Services,
LLC designates
this educational
activity for
a maximum
2.0 of
AMA PRA
Category 1
Credit(s)TM. Physicians
should only
claim credit
commensurate with
the extent
of their
participation in
the activity.
|
|
|
|
W H O
S H O
U L D
A T T
E N D
? |
|
|
|
This
educational
activity
is
specifically
designed
for
medical
oncologists,
dermatologists,
and
other
physicians,
physicians-in-training,
and
healthcare
professionals
interested
in
and/or
involved
in
the
care
of
patients
with
melanoma
and
its
consequences.
No
specialized
knowledge
or
skill
other
than
general
familiarity
with
internal
medicine,
oncology,
or
dermatology
is
required
for
successful
participation
in
this
activity.
|
|
|
|
O B J
E C T
I V E
S |
|
|
|
After
successfully
completing
this
educational
activity,
participants
should
be
able
to:
- Describe
the
basic concepts
of immunotherapy
and how
each type
can be
used as
a treatment modality in
oncology
-
Discuss
the
role
immune
tolerance
plays
in
allowing
the
growth
and
spread
of
cancer
cells
-
Explain
the
specific
role
of
CTLA-4
in
maintaining
immune
tolerance
and
how
inhibiting
its
function
can
be
used
in
the
treatment
of
malignant
melanoma
-
Compare
and
contrast
emerging
biological
agents,
primarily
vaccines
and
cytokines,
that
are
used
to
stimulate
and
target
a
patient’s
own
immune
response
against
a
tumor
and
are
currently
in
trials
for
use
against
melanoma
|
|
|
|
|
R E G
I S T
R A T
I O N |
|
|
|
*FULL*
You may register online by August 8, 2007
or
by calling
Imedex
at
+1 (678)
242
0906.
Registration
confirmations will be issued before the meeting. This
is
a complimentary dinner meeting and space
is
limited.
To
confirm
your
attendance,
please
register
by August
8, 2007. |
|
|
|
G
E N E
R A L
I N F
O R M
A T I
O N |
|
|
|
Meeting
Location
BAR
AMERICAIN
152
West
52nd
Street
(bet.
6th
&
7th
Ave)
New
York,
New
York
10019
Tel:
+1
(212)
2265
9025
|
|
|
|
O R G
A N I
Z E R |
|
|
|
|
|
©
2007 Imedex Accreditation
Services, LLC.
All rights reserved.
Reproduction in
whole or part
is prohibited
without prior
written consent
from Imedex and
contributing faculty.
|
